Brainsway (NASDAQ:BWAY) Rating Increased to Buy at Wall Street Zen

Brainsway (NASDAQ:BWAY) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

BWAY has been the subject of a number of other research reports. Northland Securities set a $15.00 price target on Brainsway in a report on Thursday, January 22nd. HC Wainwright raised their price objective on Brainsway from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Brainsway currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Brainsway Trading Down 2.2%

NASDAQ BWAY opened at $12.34 on Friday. The company has a market cap of $483.97 million, a PE ratio of 82.27 and a beta of 1.20. The stock has a 50 day moving average of $11.75 and a 200-day moving average of $9.32. Brainsway has a 12 month low of $3.92 and a 12 month high of $13.31.

Institutional Investors Weigh In On Brainsway

Institutional investors have recently modified their holdings of the business. ARK Investment Management LLC acquired a new position in shares of Brainsway in the fourth quarter valued at about $2,422,000. Y.D. More Investments Ltd raised its stake in Brainsway by 559.8% in the 4th quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after purchasing an additional 97,537 shares in the last quarter. UBS Group AG boosted its holdings in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after purchasing an additional 60,877 shares during the period. Two Sigma Investments LP boosted its holdings in Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after purchasing an additional 20,706 shares during the period. Finally, Millennium Management LLC grew its position in shares of Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after purchasing an additional 16,354 shares in the last quarter. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.